A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
By J. Mateo, D. Chakravarty, R. Dienstmann, S. Jezdic, Abel Gonzalez-Perez, Núria López-Bigas, C. Ng, Philippe Bédard, G. Tortora, J. Douillard and 5 more. Annals of Oncology, 2018
704 citations recorded by the source corpus.
Background In order to facilitate implementation of precision medicine in clinical management of cancer, there is a need to harmonise and standardise the reporting and interpretation of clinically relevant genomics data. Methods The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to propose a classification system for molecular aberrations based on the evidence available supporting their value as clinical targets. A group of experts from several institutions was assembled to review available evidence, reach a consensus on grading criteria and present a classification system. This was then reviewed, amended and finally approved by the ESMO TR and PM WG and the ESMO leadership. Results This first version of the ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines six levels of clinical evidence for molecular targets according to the implications for patient management: tier I, targets ready for implementation in routine clinical decisions; tier II, investigational targets that likely define a patient population that benefits from a targeted drug but additional data are needed; tier III, clinical benefit previously demonstrated in other tumour types or for similar molecular targets; tier IV, preclinical evidence of actionability; tier V, evidence supporting co-targeting approaches; and tier X, lack of evidence for actionability. Conclusions The ESCAT defines clinical evidence-based criteria to prioritise genomic alterations as markers to select patients for targeted therapies. This classification system aims to offer a common language for all the relevant stakeholders in cancer medicine and drug development.
Subfields: Cancer Research, Oncology, Statistics and Probability
View Paper: https://www.semanticscholar.org/paper/4dc3ccd71221f24af1e6612cc874def3cc6660db
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
In Statistics and Probability
Citations in the corpus
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020, background): “ESCAT is a framework that ranks a match between drug and genomic alterations, according to their actionability.(14) ESCAT level I means that the match of an alteration and a drug has been validated in clinical trials, and should drive treatment decision in daily practice.”
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021, methodology): “These scores have been de fi ned by the guideline authors and validated by the ESMO Translational Research and Precision Medicine Working Group.”